Skip to main content

Brexit and the Healthcare Industry Intelligence Report 2023: Assess the Risks that the UK's Healthcare Sector is Continuing to Face - ResearchAndMarkets.com

The "Brexit and the Healthcare Industry - Thematic Intelligence" report has been added to ResearchAndMarkets.com's offering.

This report examines the business environment, weighs the challenges and opportunities, and assesses the risks that the UK's healthcare sector is continuing to face post-Brexit.

The report is based on the opinions and expectations of 120 global healthcare industry professionals surveyed from February 9, 2023, to March 6, 2023, and 85 UK physicians surveyed from January 31, 2023 to March 8, 2023, to gauge Brexit impact on the healthcare industry.

The report also highlights the impact from global inflation and measures how the UK would have performed had it not decided to rupture its ties with the EU.

  • Brexit is believed to have a greater damaging impact on the UK's healthcare sector than inflation or COVID-19
  • The majority of respondents indicated that their sentiment on the impact of Brexit on the UK's healthcare sector became more negative after the UK officially left the EU
  • Three years after official Brexit, a reversal of the referendum result still remained the best outcome of Brexit for the UK's healthcare industry
  • The majority of respondents did not believe that the UK remained an attractive destination for healthcare research and manufacturing following Brexit
  • The regulatory implications of the UK leaving the EEA were highlighted as the biggest concern post-Brexit
  • More than 50% of respondents confirmed that Brexit has had an impact on their company and corporate strategy
  • Reducing barriers to EU-UK collaboration on clinical research could help the UK's healthcare industry to thrive
  • Respondents believed that the UK's healthcare sector is worse off after Brexit

Key Highlights

  • The UK's healthcare sector is facing greater negative impact from Brexit than other macro events.
  • The result "reversal of the referendum" remained the best outcome of Brexit for the healthcare industry.
  • Regulatory divergence is the healthcare sector's main concern associated with the UK's departure from the EU.
  • The UK should reduce barriers to the UK-EU collaboration on clinical research to help its healthcare sector to thrive.
  • Brexit impact on companies and their corporate strategies in the UK and across the EU continues to materialize.
  • Departure from the EU exacerbated the challenges faced by the UK's healthcare sector.

Objectives of this report include:

  • Benchmark factors that will impact healthcare
  • Determine impact on research and manufacturing
  • Track changes to corporate strategy
  • Examine ongoing healthcare-related policies and initiatives
  • Determine changes in respondents' attitudes and perceptions
  • Assess the impact of inflation
  • Capture physicians' perception of Brexit

Reasons to Buy

  • Develop and design your corporate strategies post-Brexit through an in-house expert analysis of the key factors to impact the post-Brexit UK healthcare industry
  • Develop business strategies by understanding the key factors to impact healthcare research and manufacturing in the UK post-Brexit
  • Stay up to date on the industry's changing sentiment towards Brexit from within the healthcare industry
  • Identify emerging industry trends post-Brexit to gain a competitive advantage
  • Understand current macro events impacting healthcare industry in the UK post-Brexit.

Key Topics Covered:

1. Study Design

2. Executive Summary

3. UK Pharma Industry and Brexit

4. Outcome of Brexit

5. Factors to Impact Healthcare

6. Impact on Research and Manufacturing

7. Impact on Corporate Strategy

8. Impact on the NHS

9. Brexit and Inflation

10. Future Prospects

11. Summary of Key Findings

12. Appendix

A selection of companies mentioned in this report includes

  • Office of National Statistics
  • International Monetary Fund
  • Organisation for Economic Cooperation and Development
  • GlaxoSmithKline
  • AstraZeneca
  • Pfizer
  • Roche
  • Novartis
  • Merck
  • Bayer
  • Johnson & Johnson
  • EMA
  • MHRA
  • BioNTech
  • FDA
  • NHS
  • ABPI
  • UKRI
  • British Medical Journal
  • Bank of England

For more information about this report visit https://www.researchandmarkets.com/r/vwf3nj

Source: GlobalData

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.